This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcasts3D Body AtlasLet’s connectLet's connectContact usSign up

Menu

Close

OverviewStarting Strong in 1LAbout LORVIQUA®Study Design1L study design2L+ study designEfficacy1L overall efficacy1L CNS efficacy1L 5-Year overall efficacy1L 5-Year CNS efficacy2L+ efficacySafetyPooled Safety: all lines1L safety2L+ safetyDosing & Therapy ManagementOnce-daily dosingARs of clinical interestTherapy managementResourcesMaterialsVideos
Prescribing Information 
LORVIQUA® achieved significantly longer PFS in 1L ALK+ aNSCLC vs crizotinib1,2 Progression-free survival by BICR (ITT population, N=296)1,2

Data cutoff: 20 March 2020.2

  • In the CROWN trial, median PFS was not reached for LORVIQUA® vs 9.3 months for crizotinib (95% CI: 7.6-11.1)1
  • Longer PFS was experienced by patients taking LORVIQUA® vs crizotinib, irrespective of baseline patient and disease characteristics1,2
  • At data cutoff, OS data were not mature2
      Progression-free survival (BICR assessed): subgroup analysis2
      Insert your text here
      Insert your text here
      Insert your text here

      Lorem ipsum dolor sit amet, consectetur adipiscing elit feugiat accumsan vitae et purus.

      Data Cutoff: 20 March 2020.2
      Adapted from: Supplement to Shaw AT, Bauer TM, de Marinis F, et al: CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21): 2018-2029

      This graph depicts prespecified exploratory subgroup analyses from the CROWN trial. Small patient numbers can be a limitation of subgroup analyses. These results are presented for descriptive purposes and should not be interpreted as a demonstration of efficacy in any particular subgroup.2

      Improved tumour response with LORVIQUA® vs crizotinib1,2

      This graph depicts prespecified exploratory subgroup analyses from the CROWN trial. Small patient numbers can be a limitation of subgroup analyses. These results are presented for descriptive purposes and should not be interpreted as a demonstration of efficacy in any particular subgroup.2

      ORR (ITT population, N=296)a

      aDefined as confirmed complete response or partial response as assessed by BICR.1,2 
      Data cutoff: 20 March 2020.2

      • Median DoR:Not estimable (95% Cl, NE-NE) with LORVIQUA® vs 11 months (95% Cl, 9-13) with crizotinib1,2
      • Response duration ≥12 months: 70% with LORVIQUA vs 27% with crizotinib2
      1L= first-line; 2L= second-line; BICR=blinded independent central review; CNS=central nervous system; DoR=duration of response; ECOG PS=Eastern Cooperative Oncology Group performance status; HR=hazard ratio; ITT=intention to treat; NE=not estimable; ORR=objective response rate; OS=overall survival; PFS=progression-free survival.ReferencesReferences:

      1. Pfizer. LORVIQUA® SmPC

      2. Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer.N Engl J Med. 2020;383(21):2018-2029.
      Efficacy
      LORVIQUA® safety profile
       Review the safety
      PP-LOR-IRL-0168 | JUN2025

      Adverse events should be reported.

      If you wish to make a medical information inquiry or report an adverse event please contact Pfizer on 1800 633 363 
      or email Pfizer at [email protected] or visit www.PfizerMedicalInformation.ie

      Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

      PfizerPro AccountPfizerPro Account

      Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

      Sign in or RegisterRegisterAccountLog out

      This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

       

      This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.Registered in the Republic of Ireland No. 127002. Directors: M. Adamson (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.

       

      Copyright © 2025 Pfizer Limited. All rights reserved.

      PP-UNP-IRL-0937. July 2025
      For Healthcare Professionals in the Republic of Ireland *

      The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

      I confirm that I am a healthcare professional* resident in the Republic of Ireland.

      If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

      *The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

      Terms of use

      PP-UNP-IRL-0901. July 2025

      Yes No
      You are now leaving PfizerPro
      You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


      PP-UNP-IRL-0901. July 2025